TY - JOUR
T1 - Research Priorities in Pediatric Asthma
T2 - Results of a Global Survey of Multiple Stakeholder Groups by the Pediatric Asthma in Real Life (PeARL) Think Tank
AU - Mathioudakis, Alexander G.
AU - Custovic, Adnan
AU - Deschildre, Antoine
AU - Ducharme, Francine M.
AU - Kalayci, Omer
AU - Murray, Clare
AU - Garcia, Antonio Nieto
AU - Phipatanakul, Wanda
AU - Price, David
AU - Sheikh, Aziz
AU - Agache, Ioana
AU - Bacharier, Leonard
AU - Bonini, Matteo
AU - Castro-Rodriguez, Jose A.
AU - De Carlo, Giuseppe
AU - Craig, Timothy
AU - Diamant, Zuzana
AU - Feleszko, Wojciech
AU - Ierodiakonou, Despo
AU - Gern, James E.
AU - Grigg, Jonathan
AU - Hedlin, Gunilla
AU - Hossny, Elham M.
AU - Jartti, Tuomas
AU - Kaplan, Alan
AU - Lemanske, Robert F.
AU - Le Souef, Peter
AU - Makela, Mika J.
AU - Matricardi, Paolo M.
AU - Miligkos, Michael
AU - Morais-Almeida, Mário
AU - Pite, Helena
AU - Pitrez, Paulo M.C.
AU - Pohunek, Petr
AU - Roberts, Graham
AU - Sanchez-Garcia, Sylvia
AU - Tsiligianni, Ioanna
AU - Turner, Steve
AU - Winders, Tonya A.
AU - Wong, Gary
AU - Xepapadaki, Paraskevi
AU - Zar, Heather J.
AU - Papadopoulos, Nikolaos G.
N1 - Publisher Copyright:
© 2020 American Academy of Allergy, Asthma & Immunology
PY - 2020/6
Y1 - 2020/6
N2 - Background: Pediatric asthma remains a public health challenge with enormous impact worldwide. Objective: The aim of this study was to identify and prioritize unmet clinical needs in pediatric asthma, which could be used to guide future research and policy activities. Methods: We first identified unmet needs through an open-question survey administered to international experts in pediatric asthma who were members of the Pediatric Asthma in Real Life Think Tank. Prioritization of topics was then achieved through a second, extensive survey with global reach, of multiple stakeholders (leading experts, researchers, clinicians, patients, policy makers, and the pharmaceutical industry). Differences across responder groups were compared. Results: A total of 57 unmet clinical need topics identified by international experts were prioritized by 412 participants from 5 continents and 60 countries. Prevention of disease progression and prediction of future risk, including persistence into adulthood, emerged as the most urgent research questions. Stratified care, based on biomarkers, clinical phenotypes, the children's age, and demographics were also highly rated. The identification of minimum diagnostic criteria in different age groups, cultural perceptions of asthma, and best treatment by age group were priorities for responders from low-middle-income countries. There was good agreement across different stakeholder groups in all domains with some notable exceptions that highlight the importance of involving the whole range of stakeholders in formulation of recommendations. Conclusions: Different stakeholders agree in the majority of research and strategic (eg, prevention, personalized approach) priorities for pediatric asthma. Stakeholder diversity is crucial for highlighting divergent issues that future guidelines should consider.
AB - Background: Pediatric asthma remains a public health challenge with enormous impact worldwide. Objective: The aim of this study was to identify and prioritize unmet clinical needs in pediatric asthma, which could be used to guide future research and policy activities. Methods: We first identified unmet needs through an open-question survey administered to international experts in pediatric asthma who were members of the Pediatric Asthma in Real Life Think Tank. Prioritization of topics was then achieved through a second, extensive survey with global reach, of multiple stakeholders (leading experts, researchers, clinicians, patients, policy makers, and the pharmaceutical industry). Differences across responder groups were compared. Results: A total of 57 unmet clinical need topics identified by international experts were prioritized by 412 participants from 5 continents and 60 countries. Prevention of disease progression and prediction of future risk, including persistence into adulthood, emerged as the most urgent research questions. Stratified care, based on biomarkers, clinical phenotypes, the children's age, and demographics were also highly rated. The identification of minimum diagnostic criteria in different age groups, cultural perceptions of asthma, and best treatment by age group were priorities for responders from low-middle-income countries. There was good agreement across different stakeholder groups in all domains with some notable exceptions that highlight the importance of involving the whole range of stakeholders in formulation of recommendations. Conclusions: Different stakeholders agree in the majority of research and strategic (eg, prevention, personalized approach) priorities for pediatric asthma. Stakeholder diversity is crucial for highlighting divergent issues that future guidelines should consider.
UR - http://www.scopus.com/inward/record.url?scp=85081199992&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85081199992&partnerID=8YFLogxK
U2 - 10.1016/j.jaip.2020.01.059
DO - 10.1016/j.jaip.2020.01.059
M3 - Article
C2 - 32146166
AN - SCOPUS:85081199992
SN - 2213-2198
VL - 8
SP - 1953-1960.e9
JO - Journal of Allergy and Clinical Immunology: In Practice
JF - Journal of Allergy and Clinical Immunology: In Practice
IS - 6
ER -